GLAXF - GlaxoSmithKline plc
| Previous close | 20.39 |
| Open | 20.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.35 - 20.89 |
| 52-week range | 18.14 - 21.20 |
| Volume | 1,668 |
| Avg. volume | 1,854 |
| Market cap | 105.323B |
| Beta (3Y monthly) | 0.54 |
| PE ratio (TTM) | 42.12 |
| EPS (TTM) | 0.50 |
| Earnings date | N/A |
| Forward dividend & yield | 0.95 (4.66%) |
| Ex-dividend date | 2019-05-16 |
| 1y target est | N/A |
- Reuters - UK Focus•2 days ago
Swiss agree to extradite Chinese scientist to U.S. on theft charges
Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline. Gongda Xue, a 20-year Swiss resident, has been fighting extradition and was labelled a potential flight risk after he was detained by Swiss authorities earlier this year. The Swiss Federal Office of Justice confirmed on Wednesday that the U.S. request for his extradition was approved earlier this month, though Gongda Xue still has until mid-August to appeal to the Swiss Federal Criminal Court to block it.
- Reuters•4 days ago
GSK drug helps ovarian cancer patients live longer in late-stage study
The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca. "Zejula's potential to expand PARP use beyond BRCAm (BRCA mutation) patients, was a key justification for its Tesaro acquisition and this required a positive outcome for Zejula in the PRIMA study," Jefferies analysts said.
- Reuters - UK Focus•4 days ago
UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study
GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.
- Reuters•5 days ago
GSK in talks to name HSBC's Symonds as its next chairman - Bloomberg
Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role. Citing people familiar with the talks, Bloomberg said the appointment could happen in the coming weeks.
- Reuters•5 days ago
GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg
Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role. Citing people familiar with the talks, Bloomberg said the appointment could happen in the coming weeks.
- Reuters - UK Focus•5 days ago
GSK in talks to name HSBC's Symonds as its next chairman- Bloomberg
GlaxoSmithKline Plc is in talks to name HSBC's deputy chairman Jonathan Symonds as the next chairman of the British drugmaker, Bloomberg reported on Sunday, citing a person familiar with the matter. Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role.
- Reuters•9 days ago
GSK's two-drug HIV Dovato treatment meets main goal in study
Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies. The study evaluated the effectiveness of Dovato in adults with the HIV-1 virus, who switched to the regimen from at least a triple combination containing Gilead's Vemlidy, the British company's HIV drugs division ViiV said.
- Yahoo Finance•9 days ago
Companies to Watch: T-Mobile joins S&P 500, Tesla to ramp up production, Marriott faces lawsuit
T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch.
- Reuters - UK Focus•9 days ago
CORRECTED-UPDATE 2-GSK's two-drug HIV Dovato treatment meets main goal in study (July 10)
GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday. Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.
- Reuters - UK Focus•9 days ago
CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)
GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday. The study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults with the HIV-1 virus who switched to the regimen from at least a triple combination containing Gilead Sciences' Descovy, the British company's HIV drugs division ViiV said. The positive results further bolster GSK's efforts to challenge U.S. drugmaker Gilead, which currently leads the HIV treatment market.
- Reuters - UK Focus•9 days ago
GSK's Dovato meets primary goal in late-stage HIV study
- Business Wire•9 days ago
ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen
LONDON--(BUSINESSWIRE)-- ViiV Healthcare , the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from ...
- Reuters•11 days ago
U.S. seeks extradition of Chinese researcher in drug secrets theft
The United States wants Switzerland to extradite a Chinese researcher accused of helping his scientist sister steal secrets worth $550 million from drugmaker GlaxoSmithKline, Swiss documents released on Monday show. Gongda Xue, who is fighting extradition, has been labeled a potential flight risk, according to a Swiss Federal Criminal Court verdict, keeping him in custody pending the extradition request's resolution. U.S. allegations against Gongda Xue, 49, underscore global fears that China is using networks of highly trained nationals abroad to smuggle trade secrets to the world's second-largest economy.
- Business Wire•16 days ago
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
Deborah Waterhouse, CEO, ViiV Healthcare, said: “For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals. With around 25,000 new HIV diagnoses in Europe* every year2, and the fact that today HIV is considered a chronic condition which requires people living with HIV (PLHIV) to remain on antiretroviral (ARV) treatment for life, it is ever more important to provide innovative treatment options.
- Reuters•29 days ago
GSK offers concessions to address EU concerns over Pfizer deal
- Reuters•last month
GSK kicks off sale of $1.2 billion consumer health drugs: sources
GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.
- Reuters - UK Focus•last month
GSK kicks off sale of $1.2 bln consumer health drugs -sources
GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.
- Reuters•last month
GSK pharma head flags need for speed in high-pressure drug market
Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters. Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure.
- Reuters•last month
GSK signs up gene-editing pioneers in drug discovery alliance
GlaxoSmithKline, Britain's largest drugmaker, will pay up to $67 million (52.88 million pounds) over a five-year period for the new Laboratory for Genomics Research, which will be jointly run with the University of California and led by researchers such as Jennifer Doudna, a co-inventor of the CRISPR gene-editing technology. New gene editing tools - with CRISPR/Cas9 as the most prominent example - have thrown the door wide open for rearranging the genetic code much more precisely and at lower costs than previously possible. The technology made headlines last year when a Chinese scientist caused outrage with a claim to have "gene-edited" babies, but CRISPR/Cas9 can also be used in medical and agricultural research without interfering with the human germline.
